Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

13. April 2022 07:00 ET | Quelle: Imcyse S.A.

Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of Imotope™ IMCY-0141 for Multiple Sclerosis

IMCY-MS-001 study aims to determine safety profile, optimal dosing regimen and initial efficacySecond Imotope™ from proprietary technology platform moves into clinic; interim results are expected in...
14. März 2022 07:00 ET | Quelle: Imcyse S.A.

Imcyse to Present at Oppenheimer 32nd Annual Healthcare Conference

LIÈGE, Belgium, March 14, 2022 (GLOBE NEWSWIRE) -- Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the...
13. Januar 2022 07:00 ET | Quelle: Imcyse S.A.

Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study

Positive interim biomarker data supports specific immune signature induced by IMCY-0098 and effect on potentially pathogenic T cells Enrollment on track with half of patients dosed; recruitment...
03. November 2021 08:00 ET | Quelle: Imcyse S.A.

Imcyse Appoints Gene Mack, MBA as Chief Financial Officer

LIÉGE, Belgium, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the...
17. Februar 2021 08:00 ET | Quelle: Imcyse S.A.

Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round - Pfizer Joins as Newest Shareholder

Pfizer takes equity stake in Imcyse as part of the recently announced Rheumatoid Arthritis license agreementMajor existing shareholders participated in the roundProceeds to advance Imcyse’s pipeline...